Study of blood markers and chemotherapy response in breast cancer
Part of Cancer, Skin clinical trials.
This trial is studying tiny molecules in your blood (called microRNAs) to see if they can predict how well breast cancer responds to chemotherapy given before surgery. If you are starting neoadjuvant chemotherapy, this study may help personalize your treatment.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must have been diagnosed with breast cancer (confirmed by a biopsy).
- You are planning to get chemotherapy before surgery (neoadjuvant chemotherapy).
- You are biologically female.
- You are 18 years old or older.
- You are able to give informed consent.
- Your organs are working well enough for standard chemotherapy (your doctor will check this).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study looks at tiny particles in your blood and tumor to see if they can predict how well your chemotherapy will work for breast cancer. The goal is to help guide treatment based on your individual cancer.
This study looks at how well a computer model can predict if breast cancer will completely respond to chemotherapy before surgery. It is for people with early-stage breast cancer who are about to start neoadjuvant chemotherapy.
This study tests a personalized approach for early-stage breast cancer that is HER2-positive or triple-negative. The goal is to adjust your treatment based on how well the cancer responds to chemotherapy before surgery, so you get the right amount of radiation therapy—no more, no less.
This trial studies small particles in the blood (called extracellular vesicles) in people receiving chemotherapy before surgery for breast cancer. It may help doctors learn more about what those particles can tell them during neoadjuvant treatment.
This study looks at breast cancer samples taken by biopsy to see how tissue “molecular markers” relate to how you respond to therapy and how the cancer behaves. It may help researchers better match future treatments to the biology of your tumor.
This trial uses a special blood test to track cancer signals (called ctDNA) during and after treatment for early breast cancer. It aims to see whether monitoring these signals can help guide follow-up and treatment decisions.
Hear when a new Breast cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.